Adding to the intrigue, pramipexole, a widely employed dopamine D2‐receptor agonist traditionally used in PD treatment, has shown remarkable efficacy in promoting BNIP3‐mediated mitophagy [112]. This evidence concerns the gene BNIP3 and Parkinson disease.